It’s David vs. Goliath.
News & Analysis: Eidos Therapeutics, Inc.
BridgeBio announced this week that it had terminated its effort to acquire the remaining stake in subsidiary Eidos Therapeutics. What does this mean for Eidos shareholders?
Can their share prices continue to climb?
Pfizer and Alnylam have a fierce, young contender with a chance to catch up in a big way.
As stocks surged on positive trade news, Tesla slipped after calling off plans to go private, and Pfizer released information that caused big movements in some biotech stocks.